How should a Sequence Listing be formatted?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. A Sequence Listing must be formatted according to specific standards…

Read More

What are the restrictions on submitting copending reexamination proceedings and applications?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 5 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. The USPTO has specific restrictions regarding the submission of copending…

Read More

What does “reasonable notice” mean in the context of attorney withdrawal from patent proceedings?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-30 6 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. In the context of attorney withdrawal from patent proceedings, “reasonable…

Read More

What guidelines apply to the examination of patent applications containing nucleotide sequences?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-29 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. The examination of patent applications containing nucleotide sequences is subject…

Read More